期刊
MOLECULAR THERAPY
卷 28, 期 2, 页码 561-571出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2019.11.030
关键词
-
资金
- ZonMw grant [43400003]
- VIDI-ZonMW grant [917.11.337]
- KWF grants [UU 2010-4669, UU 2013-6426, UU 2014-6790, UU 2015-7601, UU 2018-11393]
- Gadeta
Despite extensive usage of gene therapy medicinal products (GTMPs) in clinical studies and recent approval of chimeric antigen receptor (CAR) T cell therapy, little information has been made available on the precise molecular characterization and possible variations in terms of insert integrity and vector copy numbers of different GTMPs during the complete production chain. Within this context, we characterize alpha beta T cells engineered to express a defined gamma delta T cell engineered to express a defined gamma delta T receptor (TEG) currently used in a first-in-human clinical study (NTR6541). Utilizing targeted locus amplification in combination with next generation sequencing for the vector producer clone and TEG001 products, we report on five single-nucleotide variants and nine intact vector copies integrated in the producer clone. The vector copy number in TEG001 cells was on average a factor 0.72 (SD 0.11) below that of the producer cell clone. All nucleotide variants were transferred to TEG001 without having an effect on cellular proliferation during extensive in vitro culture. Based on an environmental risk assessment of the five nucleotide variants present in the non-coding viral region of the TEG001 insert, there was no altered environmental impact of TEG001 cells. We conclude that TEG001 cells do not have an increased risk for malignant transformation in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据